Skip to main content
Top
Published in: Supportive Care in Cancer 12/2021

Open Access 01-12-2021 | Breast Cancer | Original Article

Individual courses and determinants of fear of cancer recurrence in long-term breast cancer survivors with and without recurrence

Authors: Paula Heidkamp, Clara Breidenbach, Kati Hiltrop, Christoph Kowalski, Anna Enders, Holger Pfaff, Birgitta Weltermann, Franziska Geiser, Nicole Ernstmann

Published in: Supportive Care in Cancer | Issue 12/2021

Login to get access

Abstract

Objective

This study investigated the prevalence, individual courses, and determinants of fear of cancer recurrence (FoR) in long-term breast cancer survivors (BCSs) with and without recurrence.

Methods

A total of 184 breast cancer survivors were surveyed at four measurement time points: during hospitalization (T1), 10 weeks (T2), 40 weeks (T3), and 5–6 years (T4) after hospital discharge. Descriptive statistics, chi-square tests, and logistic regression were performed.

Results

Respondents were females and 57 years old, on average. At T1, T3, and T4, 54.8%, 31.6%, and 29.7% of BCSs, respectively, were classified as having dysfunctional levels of FoR. Dysfunctional FoR decreased from T1 to T3 (χ2(1) = 17.11, p = 0.000; N = 163) and remained stable afterwards. Eight subgroups of individual courses of FoR over time could be described: (1) constant functional FoR; (2) constant dysfunctional FoR; (3) improving from dysfunctional to functional FoR from T1 to T3; (4) improving from dysfunctional to functional FoR from T3 to T4; (5) worsening from functional to dysfunctional FoR from T1 to T3; (6) worsening from functional to dysfunctional FoR from T3 to T4; (7) dysfunctional FoR at T1 and T4, and functional FoR in between; and (8) functional FoR at T1 and T4, and dysfunctional FoR in between. Logistic regression analysis revealed that being divorced/widowed, showing high levels of fatigue, being treated by chemotherapy, and having low confidence in treatment were associated with dysfunctional FoR 5 to 6 years after diagnosis (Nagelkerkes’ Pseudo-R2 = 0.648).

Conclusions

The findings reveal that FoR is a significant issue in long-term BCSs and has the potential to become a persistent psychological strain. We emphasize the need for increased awareness of FoR among BCSs and the need for support programs.
Literature
9.
go back to reference Koch L, Bertram H, Eberle A, Holleczek B, Schmid-Höpfner S, Waldmann A et al (2014) Fear of recurrence in long-term breast cancer survivors-still an issue. Results on prevalence, determinants, and the association with quality of life and depression from the cancer survivorship–a multi-regional population-based study. Psycho-Oncology 23(5):547–54. https://doi.org/10.1002/pon.3452 CrossRefPubMed Koch L, Bertram H, Eberle A, Holleczek B, Schmid-Höpfner S, Waldmann A et al (2014) Fear of recurrence in long-term breast cancer survivors-still an issue. Results on prevalence, determinants, and the association with quality of life and depression from the cancer survivorship–a multi-regional population-based study. Psycho-Oncology 23(5):547–54. https://​doi.​org/​10.​1002/​pon.​3452 CrossRefPubMed
21.
go back to reference Sobin LH, Gospodarowicz MK, Wittekind C (2011) TNM Classification of Malignant Tumours, 7th edn. Wiley, Somerset Sobin LH, Gospodarowicz MK, Wittekind C (2011) TNM Classification of Malignant Tumours, 7th edn. Wiley, Somerset
27.
go back to reference Lazarus RS, Folkman S 1984 Stress, appraisal, and coping Lazarus RS, Folkman S 1984 Stress, appraisal, and coping
Metadata
Title
Individual courses and determinants of fear of cancer recurrence in long-term breast cancer survivors with and without recurrence
Authors
Paula Heidkamp
Clara Breidenbach
Kati Hiltrop
Christoph Kowalski
Anna Enders
Holger Pfaff
Birgitta Weltermann
Franziska Geiser
Nicole Ernstmann
Publication date
01-12-2021
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 12/2021
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-021-06329-z

Other articles of this Issue 12/2021

Supportive Care in Cancer 12/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine